Merck & Co Inc

NYSE:MRKUnited States

Nov 15, 2024

Show headlines and story abstract

• Jefferies Adjusts Price Target on Merck to $148 From $147, Maintains Buy Rating, from 9:23AM ET on Friday Nov 15, 2024 by MT Newswires

  9:23AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: MRK
  09:23 AM EST, 11/15/2024 (MT Newswires) -- Merck (MRK) has an average outperform rating and a price target range of $100 to $155, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major ban...

• Merck Says EU Panel Endorses Keytruda Combination Therapy in Pleural Mesothelioma, from 8:19AM ET on Friday Nov 15, 2024 by MT Newswires

  8:19AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: MRK
  08:19 AM EST, 11/15/2024 (MT Newswires) -- Merck (MRK) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of the company's Keytruda drug combined with pemetrexed and platinum ...

• DJ Merck Gets CHMP Backing of Keytruda in Malignant Pleural Mesothelioma, from 7:54AM ET on Friday Nov 15, 2024 by Dow Jones

  7:54AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: MRK
  
  By Colin Kellaher
  
  Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain patients with a rare cancer of the lining around the lungs.
  

• Merck Receives Positive EU CHMP Opinion for KEYTRUDA(R) (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM), from 7:15AM ET on Friday Nov 15, 2024 by Dow Jones

  7:15AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: MRK
  
  Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit http://www.merck.com/research/oncology.
  

• DJ Merck Initiated at Peer Perform by Wolfe Research, from 5:43AM ET on Friday Nov 15, 2024 by Dow Jones

  5:43AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: MRK
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MRK/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 15, 2024 05:43 ET (10:43 GMT)